Photographs of a patient with dermatomyositis with refractory skin disease before and after taking lenabasum (IMAGE)

Elsevier

Photographs of a patient with dermatomyositis with refractory skin disease before and after taking lenabasum

Caption

Top row: Baseline with dark red erythema of the upper lateral arms (left) versus last visit with pink erythema and decreased surface area from baseline (right). Bottom row: baseline with dark red erythema of chest (left) versus last visit with pink erythema and poikiloderma of chest (right).

Credit

Werth VP, et al. Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial. J Invest Dermatol, https://doi.org/10.1016/j.jid.2022.03.029).

Usage Restrictions

Please include attribution.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.